Pfizer buys two Baxter vaccines
Pfizer is spending $635 million to broaden its vaccines portfolio. Reuters reports that the company is purchasing two vaccines from Baxter. Both vaccines are sold outside of the United States. One vaccine is for meningitis, the other for encephalitis. The two earned around $300 million combined last year.
The purchase is part of Baxter's decision to split into Baxter BioScience, which is focused on blood disorders, and Baxter, which will sell products including IV solutions and equipment.